http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2722720-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78d390f4b6c1b36e138f3ddebfb5455b |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D453-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D453-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-439 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D453-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D453-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D403-12 |
| filingDate | 2017-12-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_382d9fe1cd49558bf58952a651ac7b58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9d73fadf5c9fd0252bf8257d9b5039c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe9e8b19091a30e9a0061b841db9157c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94e10676b6d4c2e29931c409e3d4f050 |
| publicationDate | 2020-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2722720-C1 |
| titleOfInvention | Class of bifunctional compounds with quaternary ammonium salt structure |
| abstract | FIELD: chemistry.SUBSTANCE: invention relates to compounds of formula (I) with bifunctional structure of quaternary ammonium salt with agonist activity β-adrenoreceptor and muscarinic receptor antagonist, a pharmaceutically acceptable salt thereof and an optical isomer, as well as a pharmaceutical composition, a method for production thereof and use thereof. In general formula (I) L is (4-10C) aryl or heteroaryl, where heteroatom heteroaryl is selected from N, O and S, and said groups can be unsubstituted or optionally substituted with one or more substitutes selected from halogen, -OR, -SR, -NRR, -NHCOR, -CONRR, -CN, -NO, -COOR, -CFand C-Cunbranched or branched hydrocarbyl; W is independently selected from substituted or unsubstituted (3-6C) cycloalkyl, substitute selected from halogen, (1-4C) alkyl, (1-4C) alkoxy, alkoxyhydrocarbyl and heterocycle; R1 is a divalent group -(R)-(A)-(R)-; where d, e and f are each independently selected from 0, 1, 2 or 3 and the number of adjacent atoms in the shortest chain between two nitrogen atoms, to which Ris attached, ranges from 3 to 14; Rand Rare each independently selected from (1-10C) alkylene, (2-10C) alkenylene, (1-4C) alkyleneoxy, alkyleneoxyalkyl, alkylene amido, alkyleneacyloxy and alkyleneamino, where each of alkylene, alkenylene, alkyleneoxy, alkyleneoxyalkyl, alkyleneamino, alkyleneacyloxy, alkylene amido is unsubstituted or substituted with substituents, independently selected from (1-4C) alkyl, chlorine, fluorine, hydroxy, phenyl and substituted phenyl, Rand Rcan be identical or different; Ais independently selected from (3-7C) cycloalkylene, (2-7C) alkylene, (6-10C) arylene, (4-9C) heteroarylene and (3-8C) heterocycloalkylene, where cycloalkylene can be unsubstituted or substituted with 1–4 substitutes independently selected from (1-6C) alkyl; each of arylene, heteroarylene and heterocycloalkylene can be unsubstituted or substituted with 1–3 substitutes independently selected from halogen, (1-6C) alkyl, (1-6C) alkoxy, -S-(1-4C) alkyl, -S(O)-(1-4C) alkyl, -S(O)2-(1-4C) alkyl, -C(O)-O-(1-4C) alkyl, -NH-(1-4C) alkyl, -N=[(1-4C)alkyl], carboxy, nitro, cyano, amido, ester group, trifluoromethyl and trifluoromethoxy; Ris independently selected from -NHCHO, -CHOH, -NH-; Ris independently selected from -H, -CH=CH-C(O)-, -OCHC(O)-; provided that Ris independently selected from -NHCHO or -CHOH, when Ris -H; provided that Ris -NH-, when Ris independently selected from -CH═CH-C(O)- or -OCHC(O)-, and R, Rand their carbon atoms are connected to form a ring; Y is selected from Br, Cl, I, bicarbonate, carbonate, bisulphate, sulphate, nitrate, phosphate, hydrophosphate, dihydrophosphate, phosphite, formate, acetate, propionate, isobutyrate, methanesulphonate, p-toluenesulphonate, benzoate, oxalate, tartrate, fumarate, malonate, succinate, suberate, mandelate, phthalate, benzene sulphonate, citrate, glucuronate, galactonate and amino acid radical; and T is the position of hydroxy on the benzene ring and is selected from the ortho- or meta-position of Ron the benzene ring.EFFECT: compounds of the present invention are characterized by high selectivity with respect to the M-receptor subtype and have a lower adverse reaction and lower toxic and side effects on the treatment of pulmonary diseases, such as COPD and asthma.14 cl, 8 tbl, 158 ex |
| priorityDate | 2016-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 704.